444805-28-1
Chemical Structure
Brincidofovir
Synonym(s): CMX001; HDP-CDV
- CAS No.: 444805-28-1
- Formula:C27H52N3O7P
- Molecular Weight:561.69
IUPAC Name: 3-(hexadecyloxy)propyl hydrogen ((((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonate
InChIKey: WXJFKKQWPMNTIM-VWLOTQADSA-N
SMILES: NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O
Biological Activity: Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Brincidofovir | 99.72% | Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Brincidofovir-d6 | Brincidofovir-d6 (CMX001-d6) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. [Content Brief]
- [2]. Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40(6):e364-e368. [Content Brief]
- [3]. Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89(6):3295-3307. [Content Brief]
- [4]. Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9(11):320. [Content Brief]
Keywords
